NCT04854551

Opioid Modulation and Neural Reward Activation in Healthy Adults

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

This is a double blind study of the effects of opioid antagonism on the brain's reward response. The investigators will recruit participants to undergo two scans, one on active medication and one on placebo. During the scan, the investigators will assess reward.

Detailed description

The study will employ a crossover design. The study will use the monetary incentive delay task during functional MRI to assess reward. This task presents participants with cues indicating whether they are playing to win $5, win $0, or to avoid losing $5. This task has been well-validated to elicit activation in a key reward response area of the brain called the ventral striatum.

Conditions

• Alcohol Drinking
• Opioid Use, Unspecified

Interventions

Type	Name	Description
DRUG	Naltrexone	Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
OTHER	Placebo	Placebo will be used to control for expectancy effects

Timeline

• Start date: 2021-05-01
• Primary completion: 2022-04-18
• Completion: 2022-04-18
• First posted: 2021-04-22
• Last updated: 2023-11-28
• Results posted: 2023-11-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study